- Home
- ALUR
as 11-15-2024 4:00pm EST
Stocks
Allurion Technologies Inc is a medical device company that focuses on creating a best-in-class weight loss platform to treat overweight patients. Its platform, the Allurion Program, features the world's first and only swallowable, procedure-less intragastric balloon for weight loss and offers access to AI-powered remote patient monitoring tools, a proprietary behavior change program, secure messaging, and video telehealth that are delivered by the Allurion VCS. Its proprietary intragastric balloon, the Allurion Balloon, is in the form of a swallowed capsule that is administered to patients under the guidance of a healthcare provider without surgery, endoscopy, or anesthesia.
| Founded: | 2009 | Country: | United States |
| Employees: | N/A | City: | NATICK |
| Market Cap: | 44.4M | IPO Year: | N/A |
| Target Price: | $3.00 | AVG Volume (30 days): | 234.0K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.48 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.31 - $4.54 | Next Earning Date: | 11-13-2024 |
| Revenue: | $34,754,000 | Revenue Growth: | -46.05% |
| Revenue Growth (this year): | -23.83% | Revenue Growth (next year): | 29.62% |
Latest Allurion Technologies Inc. News
ALUR Breaking Stock News: Dive into ALUR Ticker-Specific Updates for Smart Investing
Simply Wall St.
a day ago
Earnings Release: Here's Why Analysts Cut Their Allurion Technologies Inc. (NYSE:ALUR) Price Target To US$1.83
Simply Wall St.
2 days ago
Allurion Technologies Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Business Wire
4 days ago
Allurion Reports Third Quarter 2024 Financial Results and Provides Business Update
Business Wire
13 days ago
Allurion Presents Data From Largest Ever Real-World Experience of 19,428 Patients at The Obesity Society’s Annual Conference
Business Wire
18 days ago
Allurion to Report Third Quarter 2024 Financial Results on November 13, 2024
Business Wire
25 days ago
Allurion Announces Submission of First Three Modules of Premarket Approval Application to the U.S. Food and Drug Administration for the Allurion Balloon
Business Wire
a month ago
Allurion Announces Publication of New Data Demonstrating Muscle Mass Preservation in Patients Experiencing 15% Weight Loss
Business Wire
2 months ago
Allurion Announces Publication of Meta-Analysis Demonstrating the Safety and Effectiveness of the Allurion Program for Weight Loss
Compare ALUR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ALUR Allurion Technologies Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.